SCIENCE THAT moves^TM

Science never stands still. We drive it forward, accelerating high-impact therapies in autoimmune diseases and cancer by uniting exceptional scientific expertise, strategic risk-taking, and rigorous decision-making to improve peoples’ lives.

At Cullinan Therapeutics, we believe in a future where people living with autoimmune diseases and cancer spend less time managing their conditions and more time on what matters most.

WHERE SPEED MEETS STRATEGY

Our clinical-stage pipeline reflects a deliberate approach of advancing only the most promising molecules to address high unmet needs and achieve the greatest potential impact for people living with autoimmune diseases and cancer.

Explore our pipeline

LATEST UPDATES

CULLINAN SHARES NEW CLINICAL DATA ACROSS ITS T CELL ENGAGER PORTFOLIO IN AUTOIMMUNE DISEASES

Cullinan’s Immunology Day for investors and analysts featured new clinical data for Cullinan’s CD19- and BCMA-targeted T cell engagers in autoimmune diseases

CULLINAN PRESENTS INITIAL CLINICAL DATA FOR CLN-978, A CD19XCD3 T CELL ENGAGER, AT EULAR 2026

CLN-978 data demonstrate clinical benefit following a single target dose, deep, dose-dependent B cell depletion, and favorable safety profile in refractory SLE and difficult-to-treat RA

CULLINAN TO HOST IMMUNOLOGY DAY SHOWCASING PROMISING INITIAL CLN-978 AND VELINOTAMIG DATA

Immunology Day on June 10 for analysts and investors will feature new and updated clinical data for Cullinan’s CD19- and BCMA-targeted T cell engagers in autoimmune diseases

INNOVATING WITH INTENT

The best science not only moves forward — it moves people. Our approach to therapeutic innovation centers around leveraging our deep expertise in immune modulation to deliberately develop and advance therapies that deliver meaningful outcomes for patients and their loved ones.

Discover our approach to autoimmune diseases and cancer

SCIENCE THAT movesTM